Skip to main content

Publications

Found 81 results
Author Title [ Year(Asc)]
Filters: Author is Laura A Magee  [Clear All Filters]
2018
Ukah V, Payne BA, Hutcheon J, Ansermino JM, Ganzevoort J, Thangaratinam S, et al.. Assessment of the fullPIERS Risk Prediction Model in Women With Early-Onset Preeclampsia. Hypertension. 2018;71(4):659-665.  (237.99 KB)
Magee LA, Synnes A, von Dadelszen P, Hutfield A, Chanoine J-P, Côté A-M, et al.. CHIPS-Child: Testing the developmental programming hypothesis in the offspring of the CHIPS trial. Pregnancy Hypertens. 2018;14:15-22.  (1011.52 KB)
Khowaja A, Mitton C, Qureshi R, Bryan S, Magee LA, von Dadelszen P, et al.. A comparison of maternal and newborn health services costs in Sindh Pakistan. PLoS One. 2018;13(12):e0208299.  (645.08 KB)
Payne BA, Ryan H, Bone J, Magee LA, Aarvold A, Ansermino JM, et al.. Development and internal validation of the multivariable CIPHER (Collaborative Integrated Pregnancy High-dependency Estimate of Risk) clinical risk prediction model. Crit Care. 2018;22(1):278.  (961.71 KB)
Rocha B, Mbofana F, Loquiha O, Mudenyanga C, Ukah V, Magee LA, et al.. Early diagnosis of preeclampsia using placental growth factor: An operational pilot study in Maputo, Mozambique. Pregnancy Hypertens. 2018;11:26-31.  (374.54 KB)
Pels A, Mol B, Singer J, Lee T, von Dadelszen P, Ganzevoort J, et al.. Influence of Gestational Age at Initiation of Antihypertensive Therapy: Secondary Analysis of CHIPS Trial Data (Control of Hypertension in Pregnancy Study). Hypertension. 2018;71(6):1170-1177.  (303.94 KB)
De Silva D, Synnes A, von Dadelszen P, Lee T, Bone J, Magee LA. MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)-implementation of a national guideline in Canada. Implement Sci. 2018;13(1):8.  (1.89 MB)
Ukah V, De Silva D, Payne BA, Magee LA, Hutcheon J, Brown H, et al.. Prediction of adverse maternal outcomes from pre-eclampsia and other hypertensive disorders of pregnancy: A systematic review. Pregnancy Hypertens. 2018;11:115-123.  (501.41 KB)
2017
Ukah V, Mbofana F, Rocha B, Loquiha O, Mudenyanga C, Usta M, et al.. Diagnostic Performance of Placental Growth Factor in Women With Suspected Preeclampsia Attending Antenatal Facilities in Maputo, Mozambique. Hypertension. 2017;69(3):469-474.  (378.99 KB)
Ukah V, Payne BA, Lee T, Magee LA, von Dadelszen P. External Validation of the fullPIERS Model for Predicting Adverse Maternal Outcomes in Pregnancy Hypertension in Low- and Middle-Income Countries. Hypertension. 2017;69(4):705-711.  (149.83 KB)
Bellad M, Vidler M, Honnungar N, A M, Ramadurg U, Charanthimath U, et al.. Maternal and Newborn Health in Karnataka State, India: The Community Level Interventions for Pre-Eclampsia (CLIP) Trial's Baseline Study Results. PLoS One. 2017;12(1):e0166623.  (2.12 MB)
Aarvold A, Ryan H, Magee LA, von Dadelszen P, Fjell C, Walley K. Multiple Organ Dysfunction Score Is Superior to the Obstetric-Specific Sepsis in Obstetrics Score in Predicting Mortality in Septic Obstetric Patients. Crit Care Med. 2017;45(1):e49-e57.  (910.16 KB)
Ukah V, Hutcheon J, Payne BA, Haslam M, Vatish M, Ansermino JM, et al.. Placental Growth Factor as a Prognostic Tool in Women With Hypertensive Disorders of Pregnancy: A Systematic Review. Hypertension. 2017;70(6):1228-1237.  (986.49 KB)
Sharma S, Olalekan A, Vidler M, Drebit S, Payne BA, Akeju D, et al.. A process evaluation plan for assessing a complex community-based maternal health intervention in Ogun State, Nigeria. BMC Health Serv Res. 2017;17(1):238.  (925.17 KB)
Firoz T, Makanga P, Nathan H, Payne BA, Magee LA. Reverse innovation in maternal health. Obstet Med. 2017;10(3):113-119.  (710.03 KB)
Makanga P, Schuurman N, Sacoor C, Boene H, Vilanculo F, Vidler M, et al.. Seasonal variation in geographical access to maternal health services in regions of southern Mozambique. Int J Health Geogr. 2017;16(1):1.  (9.27 MB)
Khowaja A, Mitton C, Qureshi R, Bryan S, Magee LA, von Dadelszen P, et al.. SOCIETAL PERSPECTIVE ON COST DRIVERS FOR HEALTH TECHNOLOGY ASSESSMENT IN SINDH, PAKISTAN. Int J Technol Assess Health Care. 2017;33(2):192-198.  (266.82 KB)
Ryan H, Jones M, Payne BA, Sharma S, Hutfield A, Lee T, et al.. Validating the Performance of the Modified Early Obstetric Warning System Multivariable Model to Predict Maternal Intensive Care Unit Admission. J Obstet Gynaecol Can. 2017;39(9):728-733.e3.  (176.34 KB)
Correa M, Côté A-M, De Silva D, Wang L, Packianathan P, von Dadelszen P, et al.. Visual or automated dipstick testing for proteinuria in pregnancy?. Pregnancy Hypertens. 2017;7:50-53.  (234.13 KB)
2016
Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, et al.. Can adverse maternal and perinatal outcomes be predicted when blood pressure becomes elevated? Secondary analyses from the CHIPS (Control of Hypertension In Pregnancy Study) randomized controlled trial. Acta Obstet Gynecol Scand. 2016;95(7):763-76.  (803.67 KB)
Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, et al.. The CHIPS Randomized Controlled Trial (Control of Hypertension in Pregnancy Study): Is Severe Hypertension Just an Elevated Blood Pressure?. Hypertension. 2016;68(5):1153-1159.  (476.19 KB)
Firoz T, Vidler M, Makanga P, Boene H, Chiaú R, Sevene E, et al.. Community perspectives on the determinants of maternal health in rural southern Mozambique: a qualitative study. Reprod Health. 2016;13(Suppl 2):112.  (1019.85 KB)
Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, et al.. Control of Hypertension In Pregnancy Study randomised controlled trial-are the results dependent on the choice of labetalol or methyldopa?. BJOG. 2016;123(7):1135-41.  (144.71 KB)
Ahmed R, Gafni A, Hutton E, Hu Z, Pullenayegum E, von Dadelszen P, et al.. The Cost Implications of Less Tight Versus Tight Control of Hypertension in Pregnancy (CHIPS Trial). Hypertension. 2016;68(4):1049-55.  (470.91 KB)
Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, et al.. Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. BJOG. 2016;123(7):1143-51.  (153.93 KB)
Robertson J, Lisonkova S, Lee T, De Silva D, von Dadelszen P, Synnes A, et al.. Fetal, Infant and Maternal Outcomes among Women with Prolapsed Membranes Admitted before 29 Weeks Gestation. PLoS One. 2016;11(12):e0168285.  (862.28 KB)
Houlihan S, Decarie D, Benes C, Cleve R, Vidler M, Magee LA, et al.. Magnocaine: Physical Compatibility and Chemical Stability of Magnesium Sulphate and Lidocaine Hydrochloride in Prefilled Syringes. J Obstet Gynaecol Can. 2016;38(10):936-944.e3.  (667.48 KB)
Magee LA, Côté A-M, Joseph G, Firoz T, Sia W. Obstetric medical care in Canada. Obstet Med. 2016;9(3):117-9.  (81.97 KB)
Benton S, McCowan L, Heazell AEP, Grynspan D, Hutcheon J, Senger C, et al.. Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. Placenta. 2016;42:1-8.  (475.29 KB)
Mol B, Roberts C, Thangaratinam S, Magee LA, de Groot C, Hofmeyr J. Pre-eclampsia. Lancet. 2016;387(10022):999-1011.  (128.83 KB)
von Dadelszen P, Magee LA. Preventing deaths due to the hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016;36:83-102.  (389.82 KB)
Duffy J, Hooft Jvan 't, Gale C, Brown M, Grobman W, Fitzpatrick R, et al.. A protocol for developing, disseminating, and implementing a core outcome set for pre-eclampsia. Pregnancy Hypertens. 2016;6(4):274-278.  (336.66 KB)
Ryan H, Sharma S, Magee LA, Ansermino JM, MacDonell K, Payne BA, et al.. The Usefulness of the APACHE II Score in Obstetric Critical Care: A Structured Review. J Obstet Gynaecol Can. 2016;38(10):909-918.  (304.95 KB)
Vidler M, Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, et al.. Women's views and postpartum follow-up in the CHIPS Trial (Control of Hypertension in Pregnancy Study). Eur J Obstet Gynecol Reprod Biol. 2016;206:105-113.  (412.73 KB)
2015
Payne BA, Hutcheon J, Dunsmuir D, Cloete G, Dumont G, Hall D, et al.. Assessing the incremental value of blood oxygen saturation (SpO(2)) in the miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) Risk Prediction Model. J Obstet Gynaecol Can. 2015;37(1):16-24.  (1.11 MB)
Payne BA, Groen H, Ukah V, Ansermino JM, Bhutta ZA, Grobman W, et al.. Development and internal validation of a multivariable model to predict perinatal death in pregnancy hypertension. Pregnancy Hypertens. 2015;5(4):315-21.  (505.41 KB)
Khowaja A, Mitton C, Bryan S, Magee LA, Bhutta ZA, von Dadelszen P. Economic evaluation of Community Level Interventions for Pre-eclampsia (CLIP) in South Asian and African countries: a study protocol. Implement Sci. 2015;10:76.  (1.88 MB)
Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. The hypertensive disorders of pregnancy (29.3). Best Pract Res Clin Obstet Gynaecol. 2015;29(5):643-57.  (227.04 KB)
Magee LA, Namouz-Haddad S, Cao V, Koren G, von Dadelszen P. Labetalol for hypertension in pregnancy. Expert Opin Drug Saf. 2015;14(3):453-61.  (463.16 KB)
Magee LA, Singer J, von Dadelszen P. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(24):2367-8.  (515.75 KB)
De Silva D, Sawchuck D, von Dadelszen P, Basso M, Synnes A, Liston R, et al.. Magnesium Sulphate for Eclampsia and Fetal Neuroprotection: A Comparative Analysis of Protocols Across Canadian Tertiary Perinatal Centres. J Obstet Gynaecol Can. 2015;37(11):975-87.  (362.1 KB)
Teela K, De Silva D, Chapman K, Synnes A, Sawchuck D, Basso M, et al.. Magnesium sulphate for fetal neuroprotection: benefits and challenges of a systematic knowledge translation project in Canada. BMC Pregnancy Childbirth. 2015;15:347.  (549.75 KB)
von Dadelszen P, Magee LA, Payne BA, Dunsmuir D, Drebit S, Dumont G, et al.. Moving beyond silos: How do we provide distributed personalized medicine to pregnant women everywhere at scale? Insights from PRE-EMPT. Int J Gynaecol Obstet. 2015;131 Suppl 1:S10-5.  (662.6 KB)

Pages